The IC50 of flecainide-induced inhibition of RyR2 in transgenic mouse models of CPVT is ~2 μM [32,34], i.e., in the clinical therapeutic range of flecainide. Here, RYR2 is linked to catecholaminergic polymorphic ventricular tachycardia.